Skin Diseases Treatment Industry to Reach Beyond USD 124.03 Billion 2030

Comments ยท 408 Views

The global skin diseases treatment industry combines to account for USD 88.25 billion in revenue in 2022, which is expected to reach USD 124.03 billion by 2030, growing at a cumulative rate of 4.3% over the forecast period.

Skin Diseases Treatment Industry Data Book - Acne, Actinic Keratosis, Atopic Dermatitis, Alopecia Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030

The global skin diseases treatment industry combines to account for USD 88.25 billion in revenue in 2022, which is expected to reach USD 124.03 billion by 2030, growing at a cumulative rate of 4.3% over the forecast period. 

 

Skin Diseases Treatment Industry Data Book Coverage –

 

Skin Diseases Treatment Industry Data Book Coverage Snapshot

Markets Covered

Skin Diseases Treatment Industry

USD 88.25 billion in 2022

4.3% CAGR (2022-2030)

Actinic Keratosis Treatment Market Size

USD 6.42 billion in 2022

4.20% CAGR (2023-2030)

Atopic Dermatitis Market Size

USD 14.19 billion in 2022

8.70% CAGR (2023-2030)

Alopecia Market Size

USD 8.19 billion in 2022

8.74% CAGR (2023-2030)

Acne Drugs Market Size

USD 8.43 billion in 2022

4.74% CAGR (2023-2030)

 

 

Access the Global Skin Diseases Treatment Industry Data Book, 2023 to 2030, compiled with details like market sizing & forecasts insights, regulatory & technology framework, pricing intelligence, competitive benchmarking analyses, and macro-environmental analyses studies

 

Actinic Keratosis Treatment Market Growth & Trends

 

The global actinic keratosis treatment market size is anticipated to reach USD 8.93 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 4.1% from 2022 to 2030. The market is expected to witness growth opportunities owing to factors such as the wide availability of actinic keratosis therapeutics, rising awareness about the disease, and the rise in AK treatment. Moreover, the increasing prevalence of actinic keratosis and the rising geriatric population across the globe are expected to fuel the market growth during the forecast period.

 

Invasive squamous cell carcinoma may develop from AK when it becomes malignant (iSCC). Despite the fact that there are a number of potential causes for iSCC, AK is one of the most frequent ones. Additionally, basal cell carcinoma and non-melanoma skin cancer could result from AK. As a result, the demand for AK products across sales channels is being driven by the early diagnosis and treatment of actinic keratosis as a preventive strategy for comorbidities.

In addition, future pipeline medications and the increased use of combination therapy are key market drivers. For instance, Almirall, S.A. has Klisyri (extended label) in phase III of R&D. Furthermore, a rise in the acceptance and commercialization of innovative drugs is another factor that is predicted to fuel market growth. Moreover, increased R&D activities are expected to accelerate the approval of novel drugs used in the treatment of actinic keratosis, hence, propelling the growth over the forecast period.

 

Alopecia Market Growth & Trends

 

The global alopecia market size is expected to reach USD 14.2 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.1% from 2021 to 2028. The strong presence of pipeline products and increasing approval for laser-based therapy to treat hair loss conditions are major factors anticipated to drive growth. Moreover, rising awareness among patients about alopecia and its treatments, increasing government initiatives, supportive regulations & laws, and improvements in healthcare infrastructure are factors expected to propel market growth over the forecast period.

 

Technological advancements in alopecia treatment are among the key drivers of this market. There are two FDA-approved therapeutics for alopecia-Rogaine and Propecia. There has been an increase in market penetration of generics after patent expiries of both drugs. However, the launch of several promising pipeline candidates over the forecast years such as Xeljanz (tofacitinib), Breezula (clascoterone), Jakafi (ruxolitinib), SM04554, and Lumigan (Bimatoprost) is expected to substantially drive the growth of the market in the near future.

The introduction of low-level laser therapy that helps stimulate hair growth is expected to increase the treatment rate among patients facing hair loss. In addition, the launch of laser caps, helmets, combs, and bands is also anticipated to boost the market growth. For instance, Capillus Laser Cap, iGrow Laser Helmet, iRestore Hair Growth System, and Hairmax Laser devices are some of the technologically advanced products available in the market.

 

Acne Drugs Market Growth & Trends

 

The global acne drugs market size is expected to reach USD 5.9 billion by 2025, according to a new report by Grand View Research, Inc., registering a 4.2% CAGR during the forecast period. Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.

 

Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.

Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2017, and it is expected to continue this trend through 2025. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.

By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.

 

Order your copy of the Free Sample of “Skin Diseases Treatment Industry Data Book - Acne, Actinic Keratosis, Atopic Dermatitis, Alopecia Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 – 2030” Data Book, published by Grand View Research

 

Competitive Landscape

Key players operating in the skin diseases treatment industry are –

  • Pfizer Inc.
  • AbbVie Inc.
  • Sun Pharmaceutical Industries Ltd.
  • GSK plc.
  • Amgen Inc.
  • Eli Lilly and Company
  • UCB
  • Novartis AG
  • Johnson & Johnson
  • Galderma S.A
  • AstraZeneca plc

 

 

Grand View Research’s skin diseases treatment Industry data book is a collection of market sizing information & forecasts, regulatory data, reimbursement structure, competitive benchmarking analyses, macro-environmental analyses, and regulatory & technological framework studies. Within the purview of the database, all such information is systematically analyzed and provided in the form of presentations and detailed outlook reports on individual areas of research.

 

Check out more Industry Data Books, published by Grand View Research

 

About Grand View Research

 

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

Web: https://www.grandviewresearch.com/sector-reports-list

Follow Us: LinkedIn | Twitter

 

 

Comments